Pharmaceutical

Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023

The biopharmaceutical industry experienced varied revenue shifts in 2023, with significant success for companies with obesity drugs.

Aug 1, 2024 - 04:00
Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023
The biopharmaceutical industry experienced varied revenue shifts in 2023, with significant success for companies with obesity drugs.
Read the original article

Tags:

Previous Article

Vertex’s blockbuster-in-waiting painkiller suzetrigine set for FDA review next year

Next Article

Novo faces growth challenges despite GLP-1 receptor agonist obesity boom

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NIH funds expanded access projects for ALS

NIH funds expanded access projects for ALS

Oct 6, 2023

Biogen and Neomorph enter molecular glue degrader deal

Biogen and Neomorph enter molecular glue degrader deal

Nov 1, 2024

Novel drug approvals declined in 2022 but what are the CMO opportunities in 2023?

Novel drug approvals declined in 2022 but what are the ...

Mar 27, 2023